Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Spinal muscular atrophy (SMA) prenatal carrier screening is recommended by American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG). However, in Thailand, there are no standard protocol for SMA prenatal carrier screening.
Spinal muscular atrophy (SMA) is one of the most common neuromuscular autosomal recessive disorders. The incidence is about 1:10,000 livebirths. There are 5 subgroups base on onset of symptoms and clinical severity. Type 1 is the most severe type which age of onset is 6 months old and life expectancy is less than 1-2 years. SMA carrier frequency is approximately 1/40-1/60. Molecular genetic testing to detect copies number of SMN1 gene is possible with as high as 95% detection rate. Since 2008, American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG) recommended SMA preconceptional and prenatal carrier screening in general population. In Thailand, there are no standard protocol for SMA prenatal carrier screening.
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Rate of acceptance of prenatal carrier screening for spinal muscular atrophy | Rate of acceptance of prenatal carrier screening for spinal muscular atrophy among pregnant women seeking prenatal care | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Factors associated rate of acceptance of prenatal carrier screening for spinal muscular atrophy | Factors associated rate of acceptance of prenatal carrier screening for spinal muscular among pregnant women seeking prenatal care | 12 months |
| Copies number of SMN1 and SMN2 genes in pregnant women |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
All pregnant women who came to antenatal care clinic at Ramathibodi Hospital, Mahidol University
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chayada Tangshewinsirikul | Contact | 0898905444 | chayada.tan@mahidol.ac.th | |
| Takol Chareonsirisuthigul | Contact | 021677066 | takol.cha@mahidol.ac.th |
| Name | Affiliation | Role |
|---|---|---|
| Chayada Tangshewinsirikul | Ramathibodi Hospital, Mahidol University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of Medicine, Ramathibodi Hospital, Mahidol University | Recruiting | Ratchathewi | Bangkok | 10400 | Thailand |
Not provided
| ID | Term |
|---|---|
| D009134 | Muscular Atrophy, Spinal |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D016472 | Motor Neuron Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
blood, plasma and DNA
Copies number of SMN1 and SMN2 genes in pregnant women among individuals who accepted carrier screening |
| 12 months |
| Carrier frequency among individuals who accepted carrier screening | Screen positive rate or rate of having 1 copy of SMN1 among individuals who accepted carrier screening | 12 months |
| Pregnant women's attitudes toward spinal muscular atrophy and carrier screening | After genetic counseling, pregnant women's attitudes toward spinal muscular atrophy and carrier screening will be evaluated by validated questionnaire. | 12 months |
| D019636 | Neurodegenerative Diseases |
| D009468 | Neuromuscular Diseases |